GET DAILY SIGNALSWhy Is Burning Rock Biotech (BNR) Stock Down -4.10% Today?
Key Takeaways
- BNR shares fell 4.10% in early trading, slipping to $12.87 from a prior close of $13.42.
- The decline primarily reflects profit-taking following a sharp multi-session rally that lifted the stock sharply higher in early November.
- No single company-specific catalyst was cited; the pullback appears driven by technical factors and normalizing momentum.
- The move comes amid broader volatility in small-cap and China-listed healthcare names rather than a headline-driven event.
- Traders are watching whether the stock can hold support near recent breakout levels and whether volume confirms the retracement.
- For additional detail on valuation, fundamentals, and forward-looking data, explore Price Targets, Earnings, and Forecast pages.
- To see how AI-powered trading systems are positioning across the market, explore Trending AI Robots.
Opening Summary
Burning Rock Biotech Limited (BNR), a Guangzhou-based precision oncology company focused on next-generation sequencing (NGS) diagnostics for cancer therapy selection, early detection, and minimal residual disease monitoring, traded lower on Monday. In the early session, the stock declined 4.10% to $12.87, down $0.55 from Friday's closing price of $13.42. The move marks a sharp reversal from the stock's recent upward momentum and is being attributed primarily to profit-taking rather than any single fundamental development.
Profit-Taking After a Sharp Rally
The most immediate driver behind the pullback is technical in nature. BNR entered Monday's session following a stretch of pronounced gains that lifted the stock well off its early-November levels. After trading near the $10 mark at the start of the month, shares climbed through double-digit percentage daily advances to close the prior week above $13. That kind of rapid appreciation frequently invites profit-taking as short-term traders and momentum participants lock in gains, and Monday's early decline is consistent with that dynamic.
Absence of a Single Catalyst
No specific earnings release, analyst action, or regulatory announcement accompanied Monday's move. The company's most recent financial results, reported in September, highlighted a sequential recovery in revenue, growth in its in-hospital testing business, and continued progress on product registrations in China. With no fresh company-specific headlines to absorb, the session's price action appears to reflect broader positioning and sentiment rather than a discrete news event, a common pattern for a smaller-capitalization, thinly traded stock following an outsized advance.
Market Context and Trading Activity
The decline in BNR shares is unfolding against a backdrop of elevated recent trading volume, as the stock's prior rally drew noticeably heavier participation than its typical daily average. Pullbacks that follow above-average-volume advances often signal consolidation as early buyers exit. The move also appears to diverge from any single sector-wide driver, suggesting stock-specific retracement rather than a coordinated selloff across Chinese precision-diagnostics peers. From a technical standpoint, the early weakness brings shares back toward levels tested during the prior week, leaving market participants to assess whether buyers re-emerge to defend the recent breakout zone.
What Comes Next for BNR
Looking ahead, investors will be watching whether BNR can stabilize and resume its longer-term trend. Key areas of focus include the company's upcoming quarterly results, the pace of new product registration certificates in China, and continued execution of its transition toward higher-margin in-hospital and companion-diagnostic offerings. Risks include the stock's inherent volatility, its still-developing path to profitability, and broader sentiment toward China-listed healthcare equities. Until a clearer catalyst emerges, near-term trading may remain choppy as the market digests the recent run-up.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots currently demonstrating the strongest performance under live market conditions. While Tickeron offers hundreds of automated trading bots covering thousands of tickers, only the top performers are featured in this section. The bots vary by strategy, timeframe, performance metrics, and the symbols they trade, giving traders a filtered view of what is working right now. Explore the Trending AI Robots page to see which strategies are leading today's market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BNR in downward trend: price dove below 50-day moving average on October 23, 2026
BNR moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend. In 27 of 29 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for BNR crossed bearishly below the 50-day moving average on October 27, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BNR entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on BNR as a result. In 66 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for BNR just turned positive on November 06, 2026. Looking at past instances where BNR's MACD turned positive, the stock continued to rise in 35 of 47 cases over the following month. The odds of a continued upward trend are 74%.
Following a +4.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where BNR advanced for three days, in 192 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
BNR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating fairly steady price growth. BNR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.258) is normal, around the industry mean (67.298). P/E Ratio (-1.157) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.741) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in the investment of medical fields and specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology
Industry MedicalSpecialties
Advertisement